Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26535512

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2015 Nov 5
First author
Ruan J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2016 Feb 25;374(8):793. doi: 10.1056/NEJMc1515465.
    note
    Source null
    related pmid
    26933862
    relationship
    Comment in
  2. citation
    N Engl J Med. 2016 Feb 25;374(8):792-3. doi: 10.1056/NEJMc1515465.
    note
    Source null
    related pmid
    26933863
    relationship
    Comment in

Authors and identifiers

  1. name
    Ruan J
    type
    Author
  2. name
    Martin P
    type
    Author
  3. name
    Shah B
    type
    Author
  4. name
    Schuster SJ
    type
    Author
  5. name
    Smith SM
    type
    Author
  6. name
    Furman RR
    type
    Author
  7. name
    Christos P
    type
    Author
  8. name
    Rodriguez A
    type
    Author
  9. name
    Svoboda J
    type
    Author
  10. name
    Lewis J
    type
    Author
  11. name
    Katz O
    type
    Author
  12. name
    Coleman M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ruan J
    type
    Author
  2. name
    Martin P
    type
    Author
  3. name
    Shah B
    type
    Author
  4. name
    Schuster SJ
    type
    Author
  5. name
    Smith SM
    type
    Author
  6. name
    Furman RR
    type
    Author
  7. name
    Christos P
    type
    Author
  8. name
    Rodriguez A
    type
    Author
  9. name
    Svoboda J
    type
    Author
  10. name
    Lewis J
    type
    Author
  11. name
    Katz O
    type
    Author
  12. name
    Coleman M
    type
    Author
bibliography ids
  1. nci-bib-6ad412d79e4d714f3aee8b86
book metadata
content sha256
4b5a8bb76ebf50e498c9f7cb73ea1b45cdc89e1612ef60036fcfd59b3afabbeb
document type
citation
dois
  1. 10.1056/NEJMoa1505237
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:26535512
immutable id
pubmed:26535512@4b5a8bb76ebf50e498c9f7cb73ea1b45cdc89e1612ef60036fcfd59b3afabbeb
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
19
name
The New England journal of medicine
nlm unique id
0255562
pages
1835-44
volume
373
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2016 Feb 25;374(8):793. doi: 10.1056/NEJMc1515465.
    note
    Source null
    related pmid
    26933862
    relationship
    Comment in
  2. citation
    N Engl J Med. 2016 Feb 25;374(8):792-3. doi: 10.1056/NEJMc1515465.
    note
    Source null
    related pmid
    26933863
    relationship
    Comment in
outcomes validated
false
pmid
26535512
provenance
batch id
948d34b0dea86780a31d
provider
NCBI PubMed ESummary
record sha256
5e9fa3564ef65b5c54b03d9399318fb1f1fe599ed598d40bd1d5d7930601226c
response sha256
11c34185eb9e4ea0d3c4d255d31806495349b0f097d492c4e135946541bf4bb5
retrieved at
2026-09-09T23:47:15.495091+00:00
publication date
display
2015 Nov 5
precision
day
year
2015
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, N.I.H., Extramural
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26535512/
title
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Preserved source evidence · Not medical advice